Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below Fifty Day Moving Average – Time to Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s stock price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $15.84 and traded as low as $14.84. Seres Therapeutics shares last traded at $15.15, with a volume of 52,611 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Seres Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Seres Therapeutics has a consensus rating of “Reduce” and an average price target of $14.33.

Seres Therapeutics Stock Performance

The firm has a market capitalization of $137.11 million, a price-to-earnings ratio of -4.24 and a beta of 0.22. The business has a fifty day moving average price of $15.84 and a 200 day moving average price of $16.85.

Hedge Funds Weigh In On Seres Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of MCRB. Vanguard Group Inc. grew its holdings in shares of Seres Therapeutics by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock worth $6,001,000 after purchasing an additional 19,793 shares during the period. Invesco Ltd. raised its holdings in Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 89,995 shares during the period. Vontobel Holding Ltd. lifted its position in Seres Therapeutics by 22.6% during the third quarter. Vontobel Holding Ltd. now owns 98,511 shares of the biotechnology company’s stock valued at $1,895,000 after buying an additional 18,186 shares in the last quarter. Marshall Wace LLP acquired a new position in Seres Therapeutics during the second quarter valued at approximately $1,016,000. Finally, Goldman Sachs Group Inc. grew its stake in Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after buying an additional 21,679 shares during the period. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.